Non-opioid Analgesics Market (By Drug class: NSAIDs, Acetaminophen, Local Anesthetics; By Pain Type; By Route Of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-opioid Analgesics Market 

5.1. COVID-19 Landscape: Non-opioid Analgesics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-opioid Analgesics Market, By Drug Class

8.1. Non-opioid Analgesics Market, by Drug Class, 2022-2030

8.1.1. NSAIDs

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Acetaminophen

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Local Anesthetics

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Non-opioid Analgesics Market, By Pain Type

9.1. Non-opioid Analgesics Market, by Pain Type e, 2022-2030

9.1.1. Post-operative Pain

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cancer Pain

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Neuropathic Pain

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Non-opioid Analgesics Market, By Route Of Administration 

10.1. Non-opioid Analgesics Market, by Route Of Administration, 2022-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Topical

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Injectable

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Non-opioid Analgesics Market, By Distribution Channel 

11.1. Non-opioid Analgesics Market, by Distribution Channel, 2022-2030

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Non-opioid Analgesics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.1.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.1.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.2.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.3.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.4.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Route Of Administration (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. AbbVie Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Pfizer, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Lilly

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Teva Pharmaceutical Industries Ltd.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Viatris Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Centrexion Therapeutics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Cara Therapeutics

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Medropharm GmbH

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms